First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors
March 10 2020 - 02:00AM
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq:
IPHA) (“
Innate” or the “
Company”)
today announced that the first patient was dosed in a Phase I
clinical trial evaluating IPH5201, an anti-CD39 blocking monoclonal
antibody, in adult patients with advanced solid tumors. The purpose
of the study, which is sponsored by AstraZeneca (LSE/STO/NYSE:
AZN), is to evaluate IPH5201 as monotherapy and in combination with
durvalumab (anti-PD-L1) with or without oleclumab (anti-CD73
monoclonal antibody).
The IPH5201 Phase I program is supported by
positive pre-clinical results presented at the Society for
Immunotherapy of Cancer (SITC) 2019 Congress, which demonstrated
that blocking CD39 in combination with PD-L1 checkpoint inhibitors
provides increased antitumor efficacy over PD-L1 alone and supports
the rationale for assessing this combination in clinical trials.
Pre-clinical data recently published by Innate Pharma1 also
demonstrates the rationale to further evaluate the combination of
CD39 and CD73 blockade in cancer indications, given their potential
synergistic effect on an anti-tumor response. The blockade of
CD39 not only prevents production of immunosuppressive adenosine,
but also promotes accumulation of immunostimulatory adenosine
triphosphate (ATP). It is increasingly recognized that the
adenosine pathway is critical in tumor immunosuppression.
“We’re pleased that the IPH5201 clinical studies
have started, as blockade of CD39 represents an innovative and
differentiated approach to potentially reverse immunosuppression
mediated by adenosine in the cancer microenvironment. In
particular, IPH5201’s potential to unleash immune responses makes
it an interesting molecule to investigate for the treatment of
solid tumors, particularly in combination therapies,”
said Pierre Dodion, Chief Medical Officer of Innate
Pharma. “AstraZeneca is a very valuable partner given
their expertise in the adenosine pathway and leadership in this
field. We’re excited to see our first molecule progressing to the
clinic from our multi-faceted partnership, helping to accelerate
our Company strategy and advance our immuno-oncology
portfolio.”
The multicenter, open-label, dose-escalation
Phase I study will evaluate the safety, tolerability, antitumor
activity, pharmacokinetics (PK), pharmacodynamics (PD) and
immunogenicity of IPH5201 alone, or in combination with
AstraZeneca’s anti-programmed cell death ligand 1 (PD-L1) therapy,
durvalumab, with or without its anti-CD73 monoclonal antibody,
oleclumab. More information on the Phase I
clinical trial can be found
at https://clinicaltrials.gov/ct2/show/NCT04261075.
About IPH5201:
In October 2018, Innate Pharma and AstraZeneca entered into a
development collaboration and option agreement for further
co-development and co-commercialization for IPH5201.
IPH5201 is a blocking antibody targeting the
CD39 immunosuppressive pathway.
CD39 is an extracellular enzyme that is
expressed in the tumor microenvironment, on both tumor infiltrating
cells and stromal cells in several cancer types. CD39 inhibits the
immune system by degrading adenosine tripohsphate (ATP) into
adenosine monophosphate (AMP), that is then further degraded into
adenosine by CD73. By promoting the accumulation of
immune-stimulating ATP, and preventing the production of
immune-suppressive adenosine, the blockade of CD39 may stimulate
anti-tumor activity.
About Innate Pharma:
Innate Pharma S.A. is a commercial stage
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca in the US, EU and
Switzerland, was approved by the FDA in September 2018. Lumoxiti is
a first-in class specialty oncology product for hairy cell
leukemia. Innate Pharma’s broad pipeline of antibodies includes
several potentially first-in-class clinical and preclinical
candidates in cancers with high unmet medical need.
Innate has been a pioneer in the understanding
of natural killer cell biology and has expanded its expertise in
the tumor microenvironment and tumor-antigens, as well as antibody
engineering. This innovative approach has resulted in a diversified
proprietary portfolio and major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a multi-products collaboration with
AstraZeneca.
Based in Marseille, France, Innate Pharma is
listed on Euronext Paris and Nasdaq in the US.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
ISIN codeTicker
codeLEI |
FR0010331421Euronext: IPH Nasdaq: IPHA9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain
forward-looking statements, including those within the meaning of
the Private Securities Litigation Reform Act of 1995.The use of
certain words, including “believe,” “potential,” “expect” and
“will” and similar expressions, is intended to identify
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. These risks and uncertainties
include, among other things, the uncertainties inherent in research
and development, including related to safety, progression of and
results from its ongoing and planned clinical trials and
preclinical studies, review and approvals by regulatory authorities
of its product candidates, the Company’s commercialization efforts
and the Company’s continued ability to raise capital to fund its
development. For an additional discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Universal
Registration Document filed with the French Financial Markets
Authority (“AMF”), which is available on the AMF website
http://www.amf-france.org or on Innate Pharma’s website, and public
filings and reports filed with the U.S. Securities and Exchange
Commission (“SEC”), including the Company’s final prospectus dated
October 16, 2019, and subsequent filings and reports filed with the
AMF or SEC, or otherwise made public, by the Company.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Investors Innate Pharma
Danielle Spangler Tel.: +1 917 499 6240
Danielle.Spangler@innate-pharma.com Jérôme Marino Tel.: +33 (0)4 30
30 30 30 investors@innate-pharma.com |
Media Innate Pharma Tracy
Rossin (Global/US) Tel.: +1 240 801 0076
Tracy.Rossin@innate-pharma.com ATCG Press Marie
Puvieux (France) Tel.: +33 (0)9 81 87 46 72
innate-pharma@atcg-partners.com |
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024